The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma
Abstract
Purpose: Nineteen patients with high-risk resected stage III and IV melanoma were immunized with three tumor antigen epitope peptides from gp100, MART-1, and tyrosinase emulsified with adjuvant Montanide ISA 51 and received a fully human anti-cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) monoclonal antibody MDX-010. Each of three cohorts received escalating doses of antibody with vaccine primarily to evaluate the toxicities and maximum-tolerated dose (MTD) of MDX-010 with vaccine. MDX-010 pharmacokinetics and immune responses were secondary end points. Patients and Methods: Peptide immunizations with MDX-010 were administered every 4 weeks for 6 months and then every 12 weeks for 6 months. A leukapheresis to obtain peripheral-blood mononuclear cells for immune analyses was performed before treatment and after the sixth vaccination. Patients were observed until relapse. Results: Grade 3 gastrointestinal (GI) toxicity (diarrhea or abdominal pain) was observed in three patients in the highest dose cohort and one in the middle dose cohort who seemed to be autoimmune. That defined the MTD with vaccine on this schedule at 1 mg/kg. Of eight patients with evidence of autoimmunity, three have experienced disease relapse. Of 11 patients without autoimmune symptoms, nine have experienced disease relapse. Significant immune responses were measured by tetramer and enzyme-linked immunospot assays against gp100 and MART-1. Conclusion: Dose-related autoimmune adverse events, predominantly skin and GI toxicities, were reversible. Patients mounted an antigen-specific immune response to a peptide vaccine when combined with a human anti–CTLA-4 antibody.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Self-citationRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Self-citationCoinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Self-citationCancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
“0001 1-2 25 25 0 (0%) 3-4 25 23 2 (8%) 5-6 23 17 6 (26%) 7-8 7 3 4 (57%) >8 5 1 4 (80%) Total dosex (mg/kg) Median (range) 28 (3-70) 23 (3-70) 35.”
Self-citationRibas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 568
Self-citationPrognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053007 · Cited by 566
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
Cancer Immunotherapy by Dendritic Cells
Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 508
Prognostic significance of autoimmunity during treatment of melanoma with interferon
Krauze, M. T., Tarhini, A., Gogas, H., & Kirkwood, J. M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0247-y · Cited by 507
Voskens, C. J., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 468
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463
Self-citationIs autoimmunity the Achilles' heel of cancer immunotherapy?
June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 445
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407
Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
Caturegli, P., Di Dalmazi, G., Lombardi, M., Grosso, F., Larman, H. B., Larman, T., Taverna, G., Cosottini, M., & Lupi, I. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.08.020 · Cited by 381
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Robert, L., Tsoi, J., Wang, X., Emerson, R., Homet, B., Chodon, T., Mok, S., Huang, R. R., Cochran, A. J., Comin-Anduix, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2648 · Cited by 376
Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S. R., Morris, L. E., Holland, H. K., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168468 · Cited by 364
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Immunodeficiency and immunotherapy in multiple myeloma
Pratt, G., Goodyear, O., & Moss, P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06705.x · Cited by 341
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 336
Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Tsang, K. Y., Poole, D. J., Parnes, H. L., Wright, J. J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70006-2 · Cited by 326
Fong, L., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 323
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309
Ishida, T., Ishii, T., Inagaki, A., Yano, H., Komatsu, H., Iida, S., Inagaki, H., & Ueda, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0261 · Cited by 291
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Sullivan, R. J., & Weber, J. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 291
Self-citationLocal biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses
Chen, Q., Chen, M., & Liu, Z. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00271e · Cited by 288
Weber, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-864 · Cited by 286
Self-citationCostimulatory and coinhibitory receptors in anti‐tumor immunity
Driessens, G., Kline, J., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 286
Systematic review: colitis associated with anti‐CTLA‐4 therapy
Gupta, A., De Felice, K. M., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 273
Interferon-α and cancer: Mechanisms of action and new perspectives of clinical use
Ferrantini, M., Capone, I., & Belardelli, F. (2007) · Biochimie · doi:10.1016/j.biochi.2007.04.006 · Cited by 268
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Iyer, P. C., Cabanillas, M. E., Waguespack, S. G., Hu, M. I., Thosani, S., Lavis, V. R., Busaidy, N. L., Subudhi, S. K., Diab, A., & Dadu, R. (2018) · Thyroid · doi:10.1089/thy.2018.0116 · Cited by 238
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Min, L., Vaidya, A., & Becker, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0833 · Cited by 179
Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157
“HLA-DR is a surface marker of T-cell activation after exposure to CTLA4 blocking antibodies (8, 9, 25), whereas CD45RO is a marker of prior cognate antigen-exposed T cells.”
Johnston, R. L., Lutzky, J., Chodhry, A., & Barkin, J. S. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0641-z · Cited by 135
Arigami, T., Uenosono, Y., Hirata, M., Yanagita, S., Ishigami, S., & Natsugoe, S. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01877.x · Cited by 92
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Overcoming immunological tolerance to melanoma: targeting CTLA-4
HODI, F. S. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01271.x · Cited by 36
Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies
Weide, B., Di Giacomo, A. M., Fonsatti, E., & Zitvogel, L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.016 · Cited by 21
Metadata
- Authors
- Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., Yellin, M., & Weber, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-01
- Volume
- 23
- Issue
- 4
- Pages
- 741-750
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2146887062
- Cited by
- 434
- References
- 37
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.